Indacrinone
|
|
| Systematic (IUPAC) name |
|---|
|
[(6,7-Dichloro-2-methyl-1-oxo-2-phenyl-2,3-dihydro-1H-inden-5-yl)oxy]acetic acid |
| Clinical data |
|---|
| Identifiers |
|---|
|
56049-88-8 |
|---|
| PubChem |
CID 42266 |
|---|
| ChemSpider |
38545 |
|---|
| Chemical data |
|---|
| Formula |
C18H14Cl2O4 |
|---|
|
365.21 g/mol |
|---|
SMILES
- CC1(Cc2cc(c(c(c2C1=O)Cl)Cl)OCC(=O)O)c3ccccc3
|
InChI=1S/C18H14Cl2O4/c1-18(11-5-3-2-4-6-11)8-10-7-12(24-9-13(21)22)15(19)16(20)14(10)17(18)23/h2-7H,8-9H2,1H3,(H,21,22)
Key:PRKWVSHZYDOZLP-UHFFFAOYSA-N
|
Indacrinone is a loop diuretic. It can be used in patients of gout with hypertension as an antihypertensive because it decreases reabsorption of uric acid,[1] while other diuretics increase it.
References
- ↑ Vlasses, P. H.; Rotmensch, H. H.; Swanson, B. N.; Irvin, J. D.; Johnson, C. L.; Ferguson, R. K. (1984). "Indacrinone: Natriuretic and uricosuric effects of various ratios of its enantiomers in healthy men". Pharmacotherapy 4 (5): 272–7. PMID 6504708.
